Pacira BioSciences (PCRX) Long-Term Deferred Tax (2020 - 2026)

At the end of FY2025, Pacira BioSciences posted Long-Term Deferred Tax of $123.85 million, down 5.0% from FY2024.

• Long-Term Deferred Tax has declined for three consecutive years, though with a five-year compound annual growth rate of 3.1% (FY2020 to FY2025).
• By year, Long-Term Deferred Tax came in at $130.38 million in FY2024 (-9.8%), $144.49 million in FY2023 (-9.9%), $160.31 million in FY2022 (+4.5%) and $153.36 million in FY2021 (+44.5%).
• Five-year quarterly Long-Term Deferred Tax spans a low of $93.27 million in Q3 2021 and a high of $169.28 million in Q1 2022.
• Year over year, Long-Term Deferred Tax has now declined in each of the last 14 quarters, with an average decline of 7.3% over the last eight quarters.
• The high point for year-over-year Long-Term Deferred Tax in five years was Q2 2022 (growth of 69.5%); the low point was Q1 2024 (a decline of 15.8%).
• Per Business Quant data, the three quarters before Q2 2026 came in at $122.12 million (Q1 2026), $123.85 million (Q4 2025) and $120.19 million (Q3 2025).